741705-20-4Relevant academic research and scientific papers
SUBSTITUTED 6, 7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE 10A)
-
Paragraph 0441; 0442, (2015/06/17)
The invention relates to compounds of the formula or a pharmaceutically acceptable salt thereof, wherein R′, R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINE DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A)
-
Page/Page column 92; 95, (2014/05/24)
The invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R', R1 through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
Synthesis, biological evaluation, and in vivo imaging of the first camptothecin-fluorescein conjugate
Chevalier, Arnaud,Dubois, Martine,Le Joncour, Vadim,Dautrey, Sébastien,Lecointre, Céline,Romieu, Anthony,Renard, Pierre-Yves,Castel, Hélène,Sabot, Cyrille
, p. 1119 - 1133 (2013/08/23)
The first synthesis and photophysical properties of a fluorecently labeled camptothecin derivative, namely, camptothecin-FI (CPT-FI), an antitumoral agent that targets topoisomerase I, are reported. The preparation of this fluorescent conjugate is based o
SUBSTITUTED 6,7-DIALKOXY-3-ISOQUINOLINOL DERIVATIVES AS INHIBITORS OF PHOSPHODIESTERASE 10 (PDE10A)
-
Page/Page column 57, (2012/09/05)
The invention relates to compounds of the formula wherein R′, R1, through R7 and Ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (PDE10A) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type II diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases.
SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS
-
Page/Page column 31, (2012/11/07)
The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; wherein G is R1, R2 and R3 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.
Synthesis and SAR of 2-aryl-3-aminomethylquinolines as agonists of the bile acid receptor TGR5
Herbert, Mark R.,Siegel, Dana L.,Staszewski, Lena,Cayanan, Charmagne,Banerjee, Urmi,Dhamija, Sangeeta,Anderson, Jennifer,Fan, Amy,Wang, Li,Rix, Peter,Shiau, Andrew K.,Rao, Tadimeti S.,Noble, Stewart A.,Heyman, Richard A.,Bischoff, Eric,Guha, Mausumee,Kabakibi, Ayman,Pinkerton, Anthony B.
scheme or table, p. 5718 - 5721 (2010/11/05)
Optimization of a screening hit from uHTS led to the discovery of TGR5 agonist 32, which was shown to have activity in a rodent model for diabetes.
NOVEL 2-SUBSTITUTED CYCLIC AMINES AS CALCIUM SENSING RECEPTOR MODULATORS
-
Page 85, (2010/02/08)
The present invention relates to modulators of the calcium sensing receptor having the formula I (I) wherein Ar, X, n, R, R, R, and Q are as defined herein.
